Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse events.
Takahashi T, Al-Kofahi M, Jaber M, Bratrude B, Betz K, Suessmuth Y, Yu A, Neuberg DS, Choi SW, Davis J, Duncan C, Giller R, Grimley M, Harris AC, Jacobsohn D, Lalefar N, Farhadfar N, Pulsipher MA, Shenoy S, Petrovic A, Schultz KR, Yanik GA, Blazar BR, Horan JT, Watkins B, Langston A, Qayed M, Kean LS.
Takahashi T, et al. Among authors: blazar br.
Blood. 2023 Aug 24;142(8):700-710. doi: 10.1182/blood.2023020035.
Blood. 2023.
PMID: 37319437
Clinical Trial.